IUCRO-0498; Role of Osteocytes in Myeloma Bone Disease
A
Attaya Suvannasankha, MD
Primary Investigator
Not Recruiting
18 years - 95 years
All
Phase
N/A
4 Locations
Brief description of study
The purpose of this study is to learn if substances that may cause bone destruction are increased in blood or bone marrow.
Detailed description of study
The investigators hope to determine serum FGF23 and heparanase, Dkk1 and plasma klotho levels in patients with newly diagnosed and relapsed myeloma compared to healthy controls with this exploratory study.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Multiple Myeloma,Healthy
-
Age: 18 years - 95 years
-
Gender: All
Inclusion Criteria
English-speaking
Have no known liver or kidney disorders
Have no prior history of malignancy in the past 5 years with the exception of basal cell and squamous cell carcinoma of the skin
Exclusion Criteria
Pregnant
Allergic to xylocaine
Acute illness in the past seven days
History of bleeding disorders
Prisoners
Additional Information:English-speaking
Have no known liver or kidney disorders
Have no prior history of malignancy in the past 5 years with the exception of basal cell and squamous cell carcinoma of the skin
Exclusion Criteria
Pregnant
Allergic to xylocaine
Acute illness in the past seven days
History of bleeding disorders
Prisoners
Participants will not be paid for their participation.
Updated on
01 Aug 2024.
Study ID: 1407589587
